Senior Director, head of immunology and opportunistic epidemiology
GSK, United States
Lina completed her PhD in epidemiology from Columbia University where she was a recipient of the NCI pre-doctoral training grant. She started her journey in the pharmaceutical industry at Pfizer (2005-2019) where she spent the majority of her time working in Epidemiology, Worldwide Safety and Regulatory. She served as a lead epidemiologist for products across numerous disease areas including vaccines, oncology and rare diseases. During her time there she designed and conducted studies in support of regulatory requirements and life cycle. In 2019, Lina joined Intercept, a non-viral liver disease company focused on Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis. As a head of Medical Affairs Research, she managed a team responsible for generating evidence and bridging gaps relevant to the ongoing clinical program and commercial setting. Most recently, Lina worked as a head of Real World Evidence (RWE) of cell and gene therapies at Vertex; her team was tasked in addressing unique challenges related to the design of cell and gene therapy trials as well as interpreting and contextualizing efficacy and safety findings. At Vertex Lina collaborated extensively with the Regulatory Policy Intelligence team in review and interpretation of the regulatory guidance documents relevant to RWE. Currently, Lina is the head of immunology and opportunistic epidemiology at GSK.
Disclosure information not submitted.
Sunday, August 27, 2023
10:30 AM – 12:00 PM ADT
